Preferred Medicine Building Data for Breast Cancer MicroRNA Screening Test


Our news can be accessed here on: Genomeweb Preferred Medicine News Aug 05, 2021

Preferred Medicine, a Burlingame, California-based joint venture of two Japanese firms, has begun a multicenter trial to further validate its microRNA-based blood test for the early detection of breast cancer.

Originally posted on Aug 5, 2021

About Preferred Medicine

Preferred Medicine, Inc. is a science-driven U.S. joint venture between Preferred Networks America, Inc. and Mitsui & Co., Ltd. The company was formed in November 2018 with the goal to commercialize biomedical and healthcare solutions using machine learning and deep learning technologies. Preferred Medicine is currently developing a non-invasive liquid biopsy product focused on women with a high risk for breast cancer.

Preferred Medicine is headquartered in Burlingame, California.

Media contacts:

Preferred Medicine Inc. :

Stay Informed

Sign up to be the first to hear any updates

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Please try again.
We use cookies to provide you with a greater online experience. By using our sites, you agree to our use of cookies. See our cookie policy.